HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$16.02M

FY 2025 · Annual

+100.1% YoY

Investing Cash Flow

-$1.73M

FY 2025 · Annual

Financing Cash Flow

-$20.52M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.43M)
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
Deferred Income Tax1.14M138K(696K)3.81M(1.3M)
Stock-Based Compensation2.35M2.92M(538K)1.62M1.91M
Change in Working Capital(3.02M)1.55M5.04M1.14M4.82M
Accounts Receivables1.04M(71K)629K2.37M1.02K
Inventory1.77M(622K)(661K)(189K)1.3M
Accounts Payables(3.65M)3.24M1.99M(4.3M)857.76K
Other Working Capital(2.19M)(999K)3.08M3.26M2.66M
Other Non-Cash Items(1.19M)1.53M7.58M(1.63M)819.78K
Operating Cash Flow16.43M16.94M15.79M8M16.02M
Capital Expenditures(4.51M)(10.15M)(189K)(15K)(208.59K)
Acquisitions (Net)000(1.5M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(4.46M)(10.1M)(148K)13.25M0
Investing Cash Flow(4.51M)(10.15M)(189K)11.74M(1.73M)
Debt Repayment(11.14M)(441K)(9.46M)(21.57M)(18.07M)
Common Stock Issued00000
Common Stock Repurchased(47K)(998K)(1.55M)(600K)(1.83M)
Dividends Paid(5.12M)(4.96M)(2.4M)00
Other Financing Activities4.91M(455K)(1.23M)(1.19M)(624.75K)
Financing Cash Flow(11.4M)(6.86M)(14.64M)(23.36M)(20.52M)
Effect of Forex Changes46K(394K)268K(870K)(343.66K)
Net Change in Cash567K(456K)1.23M(4.5M)(6.58M)
Free Cash Flow11.92M6.79M15.6M7.99M15.81M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$12.4M
+ D&A$22.2M
+ Stock-Based Comp$1.9M
- Deferred Tax-$1.3M
+ Working Capital$4.8M
+ Other Non-Cash$819.8K
= Operating Cash Flow$16.0M
- Capex-$208.6K
= Free Cash Flow$15.8M

Analysis

FY2025 free cash flow is $15.8M. FCF conversion is -127.2% of net income. Operating cash flow was $16.0M, with capex of -$208.6K. The largest bridge item is D&A at $22.2M.

Recent Filings

Recent regulatory filings

No filings found.

Does HLS.TO generate free cash flow?

HLS Therapeutics Inc. (HLS.TO) generated $15.81M of free cash flow in fiscal 2025.

How much operating cash flow does HLS.TO produce?

Operating cash flow was $16.02M, before capital expenditures of $208,589.00.